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Abstract
The initial laboratory approach in the diagnosis of allergies is to detect the type of allergic reaction, i.e. whether the patient’s allergy is mediated 
by immunoglobulin E (IgE) or not. For this purpose, the concentration of total serum IgE (tIgE) and specific IgE (sIgE) are determined. Progress in 
laboratory diagnostics is the use of component-resolved diagnosis (CRD) which implies determination of sIgE against purified native and recombi-
nant allergenic molecules. Component-resolved diagnosis is used in laboratory practice as singleplex and multiplex assays. The choice of allergen 
for singleplex assay is based on anamnesis, clinical findings of a patient and on skin prick test results. Multiplex-microarray assays simultaneously 
determine multiple sIgE’s against numerous allergens. The goal of CRD is to distinguish the true allergens from the cross-reactive allergen molecules. 
Component-resolved diagnosis allows predicting the risk of severe symptoms, as well as anticipating the development of allergies. Thus, determi-
nation of sIgE against allergenic components may significantly improve current diagnostics of allergy. Since this method is applied in laboratory 
practice just a few years, it is necessary to acquire new knowledge and experience, to establish good co-operation between specialist in medical 
biochemistry and laboratory medicine and the specialist allergologist, so that the method can be applied in a rational manner. Component-resolved 
diagnosis will significantly improve the diagnostics of IgE-mediated allergy in the future. The aim of this article is to present potentials of CRD in the 
laboratory diagnostics of allergy mediated by IgE.
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The initial laboratory approach in the diagnosis of 
allergies (such as atopic eczema, food allergy, rhi-
nitis and wheezing disorders) is to detect the type 
of allergic reaction, i.e. whether the patient’s aller-
gy is mediated by immunoglobulin E (IgE) or not. 
For this purpose, the concentration of serum total 
IgE (tIgE) is determined. Today, the determination 
of tIgE concentration, as a simple and automated 
method, is an integral part of the screening pro-
cess for subjects with atopy (1). Thereafter follows 
the procedure for identification of allergens which 
triggered allergic reaction, by determination of 
specific IgE (sIgE) against possible causative aller-
gens to which the skin test, history and clinical pic-
ture of the patient were pointed out (2,3). Determi-
nation of sIgE concentration over a number of 
years implied identification of sIgE by allergenic 
extract materials derived from natural allergen 
source materials. Progress in laboratory diagnos-
tics of IgE-mediated allergy is the use of compo-
nent-resolved diagnosis (CRD) or molecular diag-
nosis of allergies. Component-resolved diagnosis 
implies determination of sIgE concentration 
against purified native and recombinant allergenic 
molecules (4-6). Natural allergenic molecules may 
be purified by chemical, chromatographic, elec-
trophoretic and/or immunoaffinity techniques 
from allergen extracts of natural allergen source 
materials. Production of a recombinant allergen is 
a highly complex process comprising a whole se-
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ries of procedures including extraction and isola-
tion of messenger RNA (mRNA) from allergenic 
source, complementary DNA (cDNA) synthesis, 
electrophoretic separation of each component of 
the allergen source, primer preparation for poly-
merase chain reaction (PCR), multiplication of cD-
NAs of individual allergenic components and final-
ly expression of recombinant allergens (e.g. rBet v1, 
rBet v2, rBet v4, etc.) in appropriate systems, most 
commonly in bacterium Echerichia coli (7).
Component-resolved diagnosis, which is based on 
the determination of sIgE concentration against 
individual allergenic molecules, allows detection 
of sensitisation against individual components of 
the allergic source, even against those lacking in 
the allergen extract (6,8). The development of 
DNA technology has enabled the introduction of 
individual allergenic molecules into laboratory di-
agnostics of allergies. Since the CRD has been ap-
plied in recent years, future investigation will ex-
amine the diagnostic power of this currently ex-
pensive method. The aim of this article is to pre-
sent current potentials of CRD in the laboratory di-
agnostics of allergies.
Allergens
Allergens are substances that, in hypersensitive 
subjects, with a predisposition to enhanced IgE 
synthesis, may stimulate immediate-type hyper-
sensitivity reactions mediated by IgE (i.e. the type I 
hypersensitivity reaction) (9). The reaction takes 
place in two phases: a) the phase of sensitization 
against the causal allergen (IgE antibodies bind to 
high-affinity IgE receptors (FcεRI) on the surface of 
mast cells and basophil granulocytes), and b) re-
peated exposure to the same allergen, leading to 
cross-linking of IgE on sensitized cells, and the 
consequent release of mediators of allergic reac-
tion from sensitized cells. 
Genuine allergenic molecules imply major aller-
gens, which in most patients cause a primary, spe-
cies-specific sensitization (induce synthesis of sIgE) 
and consequent allergic reaction. Cross-reactive al-
lergenic molecules, due to their similarity to major/
genuine molecule, can only cause allergic reaction 
after previous contact with the main sensitizer, and 
they induce mild allergic reactions (6). Cross-reactiv-
ity occurs when the similarity with the species-spe-
cific molecule is greater than 70%, but it is rare if the 
similarity is less than 50%. At the same time, the ma-
jor epitope should be located at the molecular sur-
face accessible to its IgE antibody (10).
Immunoglobulin E can bind to a cross-reactive 
molecule within a similar type of allergen sources 
(e.g. within mites or within grasses) and can also 
bind to stable molecules with similar functions in 
the various types of allergenic components be-
longing to the same protein family (e.g. within pro-
filins, tropomyosins, lipocalins, calcium binding 
proteins, etc.) (6). It also enables detection of cross-
reactive carbohydrate determinants (CCDs), which 
have no clinical relevance (11).  
Allergens can enter the organism mostly by inha-
lation, ingestion or after skin contact (12-22).  
In everyday practice, the notion of an allergen is 
often not used precisely - sometimes this term is 
used to designate an allergenic source, sometimes 
to designate an allergenic protein, and in the last 
few years, this term is understood to mean an al-
lergenic molecule. For a better understanding, this 
can be substantiated by an example: allergenic 
sources (house dust mite) and single allergenic 
protein/molecules (Dermatohagoides pteronyssinus 
proteins Der p1, Der p2, Der p3, etc.). It is also impor-
tant to define the following terms: major, minor, 
primary, and cross-reactive allergenic molecules, 
respectively. Generally, major allergenic molecule 
may bind to IgE in > 50% of allergic patients with 
an allergy to its source react, and minor allergenic 
molecule may induce allergic reaction in < 50% of 
clinically allergic patients with an allergy to its 
source react (5,6). Genuine allergenic molecule is a 
molecule that causes specific sensitization to its 
corresponding allergen source. A primary aller-
genic molecule is the driving trigger, i.e. the origi-
nal senziting molecule in a particular patient. Ma-
jor allergenic molecules can be defined more pre-
cisely as primary or genuine allergenic molecules. 
In addition to these terms, it is important to under-
stand the phenomenon of cross-reactivity, which 
implies IgE’s ability to bind to allergenic molecules 
(homologues) other than the target allergenic 
molecules present in different species and then in-
https://doi.org/10.11613/BM.2018.020501 Biochem Med (Zagreb) 2018;28(2):020501 
  3
Dodig S, Čepelak I. Component-resolved diagnosis
duce an immune response. Therefore, due to their 
shared, similar or identical epitopes, cross-reactive 
molecules (homologues) may react with IgE in the 
same way as target allergens. Cross-reactivity will 
occur if the similarity of the primary structure with 
the target allergene molecule is greater than 50 - 
70% (6). In addition, cross-reactivity will appear if 
there is a reaction between IgE and CCDs (23-25). 
For each patient it is important to detect sensitiza-
tion to genuine allergenic molecules and to detect 
cross-reactive molecules. Co-sensitization implies 
simultaneous hypersensitivity to allergenic mole-
cules from different allergenic sources (e.g. weeds 
and birch) - this sensitization does not result in 
cross-reactivity. Attempts to define an allergen al-
ways fall into the definition of a function, accord-
ing to which allergens, originating from plants, an-
imals and microorganisms, could be defined as 
those antigens that are capable to stimulate the 
type I hypersensitivity reactions in hypersensitive 
persons. Allergens can be classified into several 
groups, such as inhalant, nutritional, contact, hy-
menoptera venom allergens, etc. (Table 1).
Currently allergens could be defined as proteins, 
glycoproteins, lipoproteins, or protein-conjugated 
haptens, which have unique molecular and struc-
tural properties [e.g. relative molecular mass (Mr) 5 
to 150, isoelectric point (pI) 4 to 7, carbohydrate 
composition, nucleotide and/or amino acid se-
quence] (26). Allergenic molecules belong to dif-
ferent protein/peptide groups with different func-
tions in the pathomechanism of allergic reactions, 
resulting in a well known and previously men-
tioned functional allergen definition (26). The main 
allergenic sources are foods, fungi, trees, weeds, 
grasses, mites, and finally animals; with the largest 
number of allergenic proteins being found in 
foods and the smallest in animals (27). Individual 
allergenic proteins/peptides belong to the follow-
ing protein groups/families: storage proteins (11S 
globulins, 2S albumins i 7S vicilins), nonspecific li-
pid transfer proteins (nsLTP), pathogen-related-
10-proteins (PR-10-P), profilins, lipid binding pro-
teins (LBP), lipocalins, calcium-binding proteins, 
enzymes, defensin-like proteins, serum albumin, 
tropomyosins, heat-shock proteins (28-45).
Each of the above mentioned proteins consists of 
a larger or smaller number of molecules that have 
stronger or less pronounced allergenicity, i.e. can 
be defined as genuine or cross-reactive allergenic 
molecules (6). So far, a number of molecules of in-
dividual allergenic proteins have been isolated 
Allergens Source Characteristics Reference
Inhalant grass, weed, tree, mites, etc.
Hypersensitivity to inhalant allergens can result in the appearance of allergic 
rhinitis, asthma or conjunctivitis. Diagnostic sensitivity and specificity of sIgE 
against alergenic extracts are different depending on the type of allergenic 
extract. The existence of cross reactivity within certain groups of allergens 
has been established, as well as between inhalant and nutritive allergens 






Food sIgE is sensitive for detecting of food-allergen sensitization, but 
clinical specificity is limited. Recently, CRD, being rapidly incorporated 
into laboratory diagnostics, enables distinguishing the genuine from 
cross-reactive allergens. Moreover, it has better diagnostic specificity than 
sIgE against allergenic extracts.
6,17-19
Contact latex, etc.
Clinical symptoms include contact dermatitis, allergic contact dermatitis 
(hypersensitivity type IV), and urticaria, angioedema, rhinitis, conjunctivitis, 
bronchospasm, and anaphylaxis (type I hypersensitivity reaction). sIgE to at 




Honey bee, wasp, 
etc.
Persons allergic to stinging insect venom are at risk for a much more serious 
allergic reaction, i.e. anaphylaxis. False positive results of sIgE are possible 
due to carbohydrate moieties of glycoproteins.
6,23-25
sIgE – specific immunoglobulin E. CRD – component-resolved diagnosis.
Table 1. Classification of allergens according to sources
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and produced, for example: birch allergen Bet v 
(Betula verrucosa) contains 8 molecules, mite aller-
gen Der p contains 23 molecules, peanut allergen 
Ara h (Arachis hypogaea) contains 17 molecules, 
honey bee allergen Api m (Apis mellifera) contains 
12 molecules, wasp allergen Ves v (Vespula vulgaris) 
contains 6 molecules, etc. (6). New molecules of al-
lergenic proteins and peptides are discovered eve-
ry day. Contemporary laboratory allergy diagnos-
tics allows identification and quantification of ex-
actly these individual molecules.
Allergen molecules as members of protein 
families
According to the function of some allergenic mol-
ecules (Table 2) it may be possible to predict the 
severity of the patient’s symptoms (6). Hypersensi-
tivity to labile proteins (e.g. CCDs, profilins) can 
cause local, milder symptoms, and hypersensitivi-
ty to stable proteins (e.g. storage proteins, PR-10-P) 
may imply a risk for systemic, more severe symp-
toms (Figure 1).
Application of single allergen molecules
For many years, in vivo and in vitro allergy diagnos-
tic procedures have applied allergenic extracts, i.e. 
mixtures of allergenic and nonallergenic mole-
cules. Purification, production and research of in-
dividual allergenic molecules dates back to 30 
years ago when the Der p1 of house dust mite Der-
matophagoides pteronyssinus was cloned in Echeri-
chia coli, resulting in the production of rabbit anti-
serum anti-Der p1, followed by cloning the cock-
roach allergen (antigen 5, now known as Dol m5), 
and the main birch allergenic molecule Bet v1 (46-
48). Since then, large numbers of purified native 
allergenic molecules and recombinant allergenic 
molecules have been isolated and produced (in-
halant and nutritive allergens, allergens from in-
sect venom, mold and latex).
The structural characteristics and functions of re-
combinant allergen molecules correspond to the 
characteristics of natural allergen molecules. Equal 
quality of recombinant molecules in all series of 
preparations and the fact that they are not subject 
to either genetic or biological variations, ensures 
excellent reproducibility of the tests in which they 
are applied (6). Scientific research with individual 
molecules includes examination of allergic reac-
tion pathomechanisms, application in skin prick 
tests (SPT), possible application in allergen-specif-
ic immunotherapy (ASIT), and ex vivo methods, 
which investigate the activation of basophilic 
granulocytes with individual allergic molecules, 
i.e. basophil activating test (BAT) (49-51). Allergen-
specific immunotherapy would be indicated if oli-
go/mono sensitization to the genuine allergenic 
molecules is confirmed. Preparations for compo-
nent-resolved immunotherapy (CRI) may be based 
on the mixtures of allergenic determinants de-
rived from one source. These preparations are de-
signed as hypoallergenic derivatives (52). Numer-
ous studies have focused on the testing of aller-
genic activity of various preparations, e.g. recom-
binant allergenic mosaics (containing ≥ 2 proteins), 
fragments, oligomers and chimeras/hybrids. To be 
effective, CRI preparations as well as SPT prepara-
tions should preserve both, allergenic activity and 
ability of induction of pro-inflammatory cytokines. 
Therefore, conformational-dependent B-cell epi-
to pes need to be removed, and T-cell epitopes to 
be preserved. For the present, these properties 
have not been achieved for most CRI preparations 
(52). When these problems would be solved satis-
factorily, individual molecule preparations will be 
able to be applied for SPT and ASIT. For now, sin-
gle native and recombinant allergens are used in 
laboratory diagnostics of allergy as CRD.
Figure 1. Increasing risk for manifestation of severe symptoms 
depending on allergenic protein type. CCD - cross-reactive 
carbo hydrate determinants. nsLTP - nonspecific lipid transport 





CCD profilins nsLTP Storage proteins PR-10-P
mild symptoms severe symptoms 
https://doi.org/10.11613/BM.2018.020501 Biochem Med (Zagreb) 2018;28(2):020501 
  5
Dodig S, Čepelak I. Component-resolved diagnosis
Protein Function Allergenic source Allergenic molecules*
Storage proteins (11S 
globulin, 2S albumin i 7S 
vicilin)
biological storages of ions and amino 
acids
plant seeds, nuts, 
milk, egg whites
Cor a9, 14  Ara h1,2,3,4,6
Ber e1, Jug r1, Ses i1
nsLTP transfer of phospholipids fruits, trees, weeds, cereals, nuts
Mal d3, Pru p 3, Cor a 8, Jug r3, Pla a3 
Amb a6, Art v3, Zea m14, Gly m1, Cas s1, 
Ara h9, 16, 17
PR-10-P defense against microbes or insects, chemicals plants Bet v1; Ara h8; Mal d1, Cas s1
profilins actin binding proteins trees, weeds, fruits Bet v2, Phl p12, Art v4, Ole, Cit s2, Cuc m2 Mus a1, Mal d4, Ara h5, Gly m3
LBP lipid binding proteins mite, cockroach, cat, dog, plants Der p2,7,13,  Der f7
lipocalins transport of hydrophobic molecules (steroids, retinol, lipids); PG synthesis cattle, dog, cat horse Bos d2,5, Can f1,2, Fel d4, Equ c1
calcium-binding proteins
enzymes transfer of calcium
trees, grass, weeds, 
fish Bet v4; Phl p7
isoflavone reductase biosynthesis of isoflavonoid phytoalexin plants Bet v6, Cor a6, Ole e12
peptidil prolyl isomerase
interconverts cis/trans isomers of 




catalyze the conjugation of reduced 
form of glutathione to xenobiotic 
substrates
Der p8, Der f8
cysteine protease catabolism and protein processing mites Der p1, Der f1
alpha-amylase hydrolyses α-bonds of large, α-linked polysaccharides mites Der p4
pectate lyase eliminative cleavage of pectate weeds Art v6
defensin-like protein antimicrobial peptides, acts as disruptors of microbial membranes weeds, nuts Amb a4, Art v1, Gly m2, Ara h12,13
serum albumin carrier protein animals Can f3, Fel d2
tropomyosins maintenance of cell morphology pan-allergen - foods, dust mite, cockroach Der p10, Bla g1
heat-shock proteins response to exposure to stressful conditions; antigen presentation mold, chestnut Alt a, Cas s9
*name of allergenic molecules according to the latin name of allergenic source (http://www.allergen.org). nsLTP - nonspecific lipid 
transfer proteins. PR-10-P - pathogen-related-10-proteins. LBP - lipid binding proteins. PG - prostaglandin.
Table 2. Function of some proteins and allergenic molecules
Methods used in component-resolved 
diagnostics
Component-resolved diagnostics is used in labo-
ratory practice in two main types of assays, i.e. as 
singleplex and multiplex assays. Singleplex assay 
implies the determination of one single allergen 
(one sample, one allergen) (53). 
The assay is based on standardized sandwich 
fluoro-immunochemical or lumino-immunochem-
ical method on a three-dimensional carrier. Aller-
gen component, covalently coupled to carrier, re-
acts with the specific IgE in the serum sample. Af-
ter washing away of non-specific IgE, enzyme-la-
belled antibodies against IgE are added, forming a 
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complex. Then, incubation and washing away of 
unbound enzyme-labeled anti-IgE are followed. 
The bound complex is then incubated with a de-
veloping agent. After stopping the reaction, sIgE is 
determined by a fluorometric or luminometric an-
alyzer (54,55). Multiplex assay is also based on 
fluoro-immunoassay. This method simultaneous 
determines the concentration of sIgE’s to a broad 
spectrum of allergen components. The difference 
exists in the immunoassay carrier and the detec-
tion method: allergen molecules (components) are 
immobilized on a solid substrate in a microarray 
format, and final image acquisition using an ap-
propriate microarray scanner. The results obtained 
must be analyzed with proprietary software (56). 
The choice of allergen for singleplex assay is based 
on anamnesis, clinical findings of a patient and on 
SPT. Multiplex-microarray assays simultaneously de-
termine multiple sIgE’s against numerous allergens, 
e.g. sIgE’s to 120 allergens. In addition to allergen sen-
sitization profiles, a list of clinically insignificant mol-
ecules is also obtained (57). The results are expressed 
semi-quantitatively in ISU-units, i.e. ISAC Standard-
ized Units for specific IgE (Table 3) according to the 
recommendations of the test manufacturer, which 
are standardized according to the World Health Or-
ganization IgE standard (WHO 75/502). 
Diagnostic accuracy of CRD varies depending on 
the type of allergens, and diagnostic sensitivity is 
greater than the diagnostic specificity. For nutriti-
tive allergens the sensitivity is in the range of 66 - 
100%, and the specificity ranges from of 0 - 95% 
(food chalenge tests were used as a gold standard) 
(58). Diagnostic accuracy of CRD for inhalant aller-
gens is difficult to determine because there is no 
gold standard but CRD results can be compared 
with the method for determining sIgE using aller-
genic extracts or with SPT results.
Benefits of the use of CRD
Component-resolved diagnosis has a significant 
contribution to the diagnosis of allergy as well as 
in therapy. The main goal is to distinguish the true 
allergens from the cross-reactive allergen mole-
cules. Therefore this method should be applied in 
the following cases: a) in patients with anaphylaxis 
caused by various cofactors (e.g. effort, non-steroi-
dal anti-inflammatory drugs), in patients with de-
layed anaphylaxis (3 - 6h) after consummation of 
red meat, or in patients with idiopathic anaphylax-
is; b) in individuals with latex allergy; c) in subjects 
with multiple hypersensitivity, i.e. sensitivity to 
pollen and plant food allergens; d) in subjects with 
food allergy - to predict the severity of symptoms, 
depending on the type of protein,  and to identifi-
cate allergens that could eventually lead to allergic 
symptoms (increased sIgE concentration - current-
ly no symptoms; sIgE are detectable in the serum 
even years before symptoms); e) to facilitate the 
choice of genuine allergen for ASIT (in individuals 
with hymenoptera venom allergy, in patients with 
pollen polysensitization and in subjects with inhal-
ant oligo/monosensitization) (8,59).
Given the different allergenicity of certain types of 
protein molecules, CRD allows predicting  the risk 
of severe symptoms, as well as anticipating the de-
velopment of allergies. Thus, determination of sIgE 
against allergenic components significantly im-
proved the diagnosis of allergy. Also, it can be ex-
pected that CDR will improve in vivo diagnostics in 
the future - scientists expect the SPT to be re-
placed with CDR (60). Besides, as the CRD enables 
identification of genuine and cross-reactive com-
ponents, this method will help in the individual-
ized approach of ASIT, since ASIT should be ap-
plied if the patient demonstrates hypersensitivity 
to genuine allergens (5,61,62).  
Necessity for careful interpretation of CRD 
results
Critical approach to the application of this method 
implies a good co-operation between the special-
Table 3. Interpretation of serum concentration of sIgE
ISU Interpretation of serum concentration of sIgE
<  0.3 undetectable or very low (0)
0.3 – 0.9 low (1)
1 – 14.9 moderate to high (2)
≥ 15 very high (3)
ISU – ISAC Standardized Units. sIgE – specific IgE.
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ist in medical biochemistry and laboratory medi-
cine and the specialist allergologist, and the com-
mon consistency in the interpretation of the ob-
tained results (63,64). The final interpretation is in-
fluenced by the pre-analytical, analytical and post-
analytical phase of the CRD. In the pre-analytic 
phase, it is necessary to be aware that expensive 
multiplex assay is not indicated according to clini-
cal symptoms of allergy. Therefore, sometimes re-
dundant results may be obtained. It is also impor-
tant to recall that the concentration of sIgE varies 
with seasonal exposure to allergens so that the 
measurement of sIgE concentration makes sense 
within two to six months after exposure to a caus-
al allergen (65). The fact that the sensitivity or 
specificity of CRD is not the same for all allergic 
molecules, refers to the analytical phase. For the 
correct interpretation (post-analytical phase) it is 
particularly important to note that increased con-
centration of a single molecule reveals hypersensi-
tivity but does not have to mean that the molecule 
is the cause of the symptoms (66). The latter may 
lead to unnecessary food elimination in case if all 
LTP will be eliminated from the diet. The results of 
a single patient should not be projected to the 
whole population, as CRD is foreseen for individu-
al diagnostics. Currently, CRD can not replace dou-
ble-blind placebo-controlled food challenge test 
in case of peanut  allergy (67).
In conclusion, CRD is a great challenge for special-
ists in medical biochemistry and laboratory medi-
cine and for specialist allergologist. The advantage 
of CRD over the current methods for determining 
the concentration of sIgE is that CRD can distin-
guish the true allergen molecules from the cross-
reactive allergen molecules; CRD enables the de-
tection of the risk of severe symptoms and pre-
dicting the development of allergies for each indi-
vidual patient. In that way the CRD provides a pos-
sibility for a personalized approach to the patient 
with allergy. 
Laboratory reports require an interpretative com-
mentary from a specialist in medical biochemistry 
and laboratory medicine to facilitate the clinical in-
terpretation of numerous data in the laboratory 
report. Continuous education of specialist in med-
ical biochemistry and laboratory medicine and ex-
pert allergologist is needed, so that this expensive 
method can be applied in a rational manner. In the 
hands of an experienced allergologist, CRD find-
ings can significantly contribute to individualized 
approach to the patient. Otherwise, this method 
may be unnecessary use of expensive reagents/
tests. 
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